Beigene
Clinical trials sponsored by Beigene, explained in plain language.
A global biotechnology company developing and commercializing cancer treatments.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New study tracks targeted drug zanubrutinib in rare blood cancer
Disease control Recruiting nowThis study is tracking how well the drug zanubrutinib works and its safety in people with Waldenström macroglobulinemia, a rare blood cancer. Researchers are especially interested in patients with specific genetic mutations and those from racial and ethnic minority groups. The st…
Sponsor: BeiGene • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New immunotherapy drug tislelizumab targets Hard-to-Treat cancers
Disease control Recruiting nowThis Phase 2 trial is testing tislelizumab, an immunotherapy drug, in 200 people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR) and have not responded to prior treatments. The drug works by blocking PD-1, helping the immune system recognize and atta…
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug targets Hard-to-Treat blood cancers in chinese trial
Disease control Recruiting nowThis study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC